Clinical trial designs for the approval of rare cancer drugs in Japan

被引：0

作者：

Noguchi, E. ^{[1
]}

Yonemori, K. ^{[1
]}

Shimoi, T. ^{[1
]}

Yunokawa, M. ^{[1
]}

Okuma, H. S. ^{[2
]}

Kawachi, A. ^{[2
]}

Kitano, A. ^{[3
]}

Nishikawa, T. ^{[2
]}

Shimomura, A. ^{[2
]}

Shimizu, C. ^{[2
]}

Takiguchi, Y. ^{[4
]}

Kawai, A. ^{[5
]}

Fujiwara, Y. ^{[2
]}

Tamura, K. ^{[2
]}

机构：

[1] Natl Canc Ctr, Rare Canc Ctr, Breast & Med Oncol, Tokyo, Japan

[2] Natl Canc Ctr, Breast & Med Oncol, Tokyo, Japan

[3] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan

[4] Chiba Univ, Grad Sch Med, Med Oncol, Chiba, Japan

[5] Natl Canc Ctr, Rare Canc Ctr, Tokyo, Japan

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

154P

引用

页数：1

共 50 条

[1] Basket trials for regulatory approval of rare cancer drugs in Japan
Hirakawa, Akihiro
ANNALS OF ONCOLOGY, 2019, 30 : 16 - 16
[2] Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs
Takehiro Hirai
Asuka Suzuki
Takao Yamori
Masaaki Matsuura
Investigational New Drugs, 2022, 40 : 142 - 150
[3] Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs
Hirai, Takehiro
Suzuki, Asuka
Yamori, Takao
Matsuura, Masaaki
INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 142 - 150
[4] Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US
Nagai, Sumimasa
Ozawa, Keiya
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (02) : 249 - 254
[5] Clinical Development and Regulatory Approval of Acute Heart Failure Drugs in Japan
Shinagawa, Kaori
CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 107 - 109
[6] Clinical Approval Success Rates for Investigational Cancer Drugs
DiMasi, J. A.
Reichert, J. M.
Feldman, L.
Malins, A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 329 - 335
[7] Innovative clinical trial designs for future antiepileptic drugs
Dichter, Marc A.
EPILEPSIA, 2007, 48 : 26 - 30
[8] A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases
Bashaw, E. D.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (04) : 327 - 329
[9] Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan
Ishiguro, Akihiro
Yagi, Satomi
Uyama, Yoshiaki
JOURNAL OF HUMAN GENETICS, 2013, 58 (06) : 313 - 316
[10] Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
Hwang, Thomas J.
Kesselheim, Aaron S.
Tibau, Ariadna
Lee, ChangWon C.
Vokinger, Kerstin N.
JCO ONCOLOGY PRACTICE, 2022, 18 (09) : 676 - E1532

← 1 2 3 4 5 →